NOVAVAX INC. overview

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial PR Newswire GAITHERSBURG, Md., June 11, 2025 Both vaccine candidates induced robust immune responses across all antigens tested No new safety signals were observed and both vaccine candidates were well tolerated consistent with past trials Novavax continues to pursue partnering opportunities to advance further...

Novavax to Participate in Upcoming Investor Conferences PR Newswire GAITHERSBURG, Md., May 29, 2025 GAITHERSBURG, Md. , May 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside Chat Date: Wednesday, June 4, 2025 Time: 2:00 – 2:30 p.m. Eastern Time (ET) Location: New York, NY Goldman Sachs 46 th Annual Global Healthcare Conference: Presentation Date:...

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine PR Newswire GAITHERSBURG, Md., May 19, 2025 Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S. Biologics License Application approval triggers $175 million Sanofi milestone payment, with additional COVID-19 vaccine milestones and ongoing tiered royalties to be recognized when earned GAITHERSBURG, Md. , May 19, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food...

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights PR Newswire GAITHERSBURG, Md., May 8, 2025 FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD- Utah study demonstrates that Nuvaxovid ® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on average Data...

Novavax to Participate in BofA Securities 2025 Health Care Conference PR Newswire GAITHERSBURG, Md., May 7, 2025 GAITHERSBURG, Md. , May 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference. Conference Details: Fireside Chat Date: Wednesday, May 14, 2025 Time: 3:00 – 3:30 p.m. Pacific Time (PT) Location: Las Vegas, NV Conference Event: Investor Meetings Date: Wednesday, May 14, 2025 A webcast of the...

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan PR Newswire GAITHERSBURG, Md., May 5, 2025 Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid ® , a protein-based, non-mRNA COVID-19 vaccine, will continue to be available in Japan , the world's third largest pharmaceutical market GAITHERSBURG, Md. , May 5, 2025 /PRNewswire/ --...

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 PR Newswire GAITHERSBURG, Md., May 1, 2025 GAITHERSBURG, Md. , May 1, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025 . Details of the event and replay are as follows: Conference call details: Date: May 8, 2025 Time: 8:30 a.m. U.S. ET URL to register phone:...

Novavax Appoints Charles Newton to Board of Directors PR Newswire GAITHERSBURG, Md., April 29, 2025 GAITHERSBURG, Md. , April 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to...